Floatz logo

DOTATOC

Pancreatic Neuroendocrine Tumor

European Institute of Oncologyprotein_peptidePhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

41 Active assets in the Pancreatic Neuroendocrine Tumor cohort.

Asset / SponsorPhaseRating
Oxodotreotide
University of Chicago
Phase 4BBB
Everolimus
Exelixis
Phase 4BBB
Irinotecan
M.D. Anderson Cancer Center
Phase 2/3BB
Oxodotreotide
National Cancer Institute (NCI)
Phase 4BB
Octreotide Pamoate
RayzeBio, Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

DOTATOC is also rated in:

digestive system neuroendocrine neoplasmDormant
B
Indicative ·
63 / 100
View asset →
neuroblastomaDormant
B
Indicative ·
60 / 100
View asset →
carcinoid tumorDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →